Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Autor:
QT Bui, Keon Wook Kang
Publikováno v:
Cancer Research. 76:P1-05
Epithelial-mesenchymal transition (EMT) is process in which epithelial cells undergo unique morphologic changes characterized by a transition from epithelial cobblestone phenotype to elongated fibroblastic phenotype (mesenchymal phenotype) leading to
Autor:
Donatella Regano, Lorena Zentilin, Mauro Giacca, Federica Maione, Federico Bussolino, Guido Serini, Enrico Giraudo, Stefania Capano
Publikováno v:
Cancer Research. 72:SY41-04
The critical role of angiogenesis in tumor development, progression and metastatization has long been appreciated and several anti-angiogenic inhibitors are approved for use in cancer therapy. Recently it has been reported in pre-clinical mouse model
Autor:
MA Sandoval, Dss Lansakara-P, Zhengrong Cui, Stephen D. Hursting, Sarah M. Dunlap, RE DeAngel
Publikováno v:
Cancer Research. 71:P1-15
Background: Excess adipose tissue plays a role in increasing breast cancer risk and tumor aggressiveness. However, the role of mature adipocytes in tumor progression and response to therapy remains unclear. Despite advances in breast cancer treatment
Autor:
Long-Wu Ye, Cheng Liu, Kim D. Janda, Dong Xue, Katerina Capkova, Subhash C. Sinha, Pengfei Jiang, Nigel Mackman, Yuan Liu
Publikováno v:
Cancer Research. 71:6492-6502
Tissue factor (TF), a rate-limiting enzyme cofactor in activating coagulation, is highly expressed in a wide spectrum of human tumor and tumor stromal cells. Using TF-deficient cancer cells and a conditional TF-knockout mouse model, we show that TF e
Autor:
Gaofeng Xiong, Ren Xu
Publikováno v:
Cancer Research. 77:5942-5942
Collagen prolyl hydroxylation (P4H), an enzyme hydroxylating proline residues in -X-Pro-Gly- sequences, is a potential therapeutic target for the disorders associated with increased collagen deposition. Upregulation of collagen prolyl-4-hydroxylase i
Publikováno v:
Cancer Research. 77:LB-327
Pancreatic ductal adenocarcinoma (PDAC) still remains to be one of the most highly malignant human diseases and is resistant to the majority of current therapeutic modalities. Oncogene MYC has been known to be upregulated in PDAC and plays a key role
Autor:
Erik Johansson, Masako Oka, Caname Iwata, Masakazu Yashiro, Yasuyuki Morishita, Kosei Hirakawa, Akiyoshi Komuro, Kohei Miyazono, Kunihiko Kiyono, Michio Kaminishi, Mitsunobu R. Kano
Publikováno v:
Cancer research. 67(21)
Cyclooxygenase-2 (COX-2) inhibitor has been reported to suppress tumor progression. However, it is unclear whether this inhibitor can also prevent lymphatic metastasis. To determine the effects of COX-2 inhibitor on lymphatic metastasis, etodolac, a
Publikováno v:
Cancer research. 67(20)
Recent clinical trials indicate that synthetic progestins may stimulate progression of breast cancer in postmenopausal women, a result that is consistent with studies in chemically-induced breast cancer models in rodents. However, progestin-dependent
Autor:
Bingcheng Wang, Aaron Petty
Publikováno v:
Cancer Research. 75:2678-2678
During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressi
Publikováno v:
Cancer Research. 75:3208-3208
Recently, tumor microenvironment has been reported to be important in carcinogenesis and tumor progression. Especially in prostate cancer (PC), it has been suggested that tumor microenvironment plays an important role in progression, acquisition of a